Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Genetic testing firm 23andMe cuts 40% of jobs and halts therapeutic programs to save costs.

flag Genetic testing company 23andMe is cutting its workforce by 40%, affecting around 200 jobs, and halting the development of its therapeutic programs in a bid to save costs and refocus on its core business. flag CEO Anne Wojcicki plans to explore strategic alternatives like licensing and asset sales for the company’s therapeutics. flag The restructuring aims to save over $35 million annually.

6 Articles

Further Reading